Shares of Vericel Corp. (NASDAQ:VCEL) were up 2.9% during trading on Friday . The stock traded as high as $2.18 and last traded at $2.15, with a volume of 74,618 shares traded. The stock had previously closed at $2.09.

Several analysts have issued reports on VCEL shares. Bank of America Corp. cut Vericel Corp. from a “buy” rating to a “neutral” rating in a report on Tuesday, April 5th. Needham & Company LLC restated a “buy” rating and issued a $12.00 target price on shares of Vericel Corp. in a report on Tuesday, April 5th.

The stock’s 50 day moving average is $2.37 and its 200 day moving average is $2.79. The company’s market capitalization is $48.68 million.

Vericel Corp. (NASDAQ:VCEL) last announced its earnings results on Tuesday, May 10th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.17. The company earned $14.10 million during the quarter, compared to analysts’ expectations of $11.60 million. On average, equities analysts anticipate that Vericel Corp. will post ($0.79) earnings per share for the current year.

Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.